SCHEDULE: Eventide Asset Management Reports 5.6% Stake in Immix Biopharma

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported beneficial ownership of 5.6% of Immix Biopharma, Inc.'s common stock as of June 30, 2026.

Summary

• Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have jointly filed a Schedule 13G.
• This filing indicates their beneficial ownership of 3,891,019 shares of Immix Biopharma, Inc. common stock.
• This ownership stake represents 5.6% of the company's outstanding common stock as of June 30, 2026.
• Eventide Asset Management, LLC is the investment adviser to the Eventide Healthcare & Life Sciences Fund, which holds these shares.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new operational or financial disclosures.

Positives

• Significant institutional ownership reported by Eventide Asset Management, LLC, indicating confidence from an investment firm.
• The reporting persons hold sole voting and dispositive power for a substantial portion of the shares, suggesting clear control over their investment decisions.

Negatives

• The filing does not provide any new financial performance data or operational updates for Immix Biopharma, Inc.

Risks

• Potential for future changes in beneficial ownership that could impact stock price or corporate control.
• The concentration of ownership among a few reporting persons could lead to significant influence on company decisions.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the future performance of Immix Biopharma, Inc.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates Eventide Asset Management's increased interest or established position in the biotechnology sector, specifically within Immix Biopharma.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a positive sign of confidence, but the lack of operational details limits immediate impact.
• Management: May need to engage with Eventide Asset Management regarding their investment strategy and potential influence.

Next Steps

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John will continue to report any material changes in their beneficial ownership of Immix Biopharma, Inc. common stock.
• Immix Biopharma, Inc. may see continued institutional interest based on this filing.

Key Dates

Keywords

Immix Biopharma, Schedule 13G, Beneficial Ownership, Eventide Asset Management, Institutional Investor, Common Stock, Investment Adviser